ADMA Biologics sets 2025 pay for CEO, COO and CFO and raises director retainers
On February 19, 2025, ADMA Biologics' board approved 2025 base salaries, 2024 cash bonuses and new equity awards for CEO Adam S. Grossman, COO Kaitlin Kestenberg and CFO Brad Tade. The board also approved a higher annual equity grant policy and higher committee retainers for non-employee directors, effective January 1, 2025.
Key points
- Grossman's 2025 base salary is $925,000 and his 2024 non-equity incentive compensation is $1,020,000.
- Grants made February 19, 2025 at $16.07 per share, the Nasdaq closing price on the grant date, include 252,022 RSUs and 376,744 options for Grossman.
- Non-employee directors will receive $350,000 of annual long-term incentive value, split 50% RSUs and 50% options.
- Audit Committee chair retainer rises to $25,000 from the filing's stated levels, effective January 1, 2025.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 21, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.